"Information Technology Methodology for Patient Motivation in Diabetes Management."

NCT ID: NCT00727896

Last Updated: 2011-06-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Type 2 diabetes is a chronic metabolic disorder requiring lifestyle modification and medicines, adherence to which has to be practised on a daily basis.

Motivation of patients to adhere to treatment is difficult in clinical practice. It is well documented that majority of patients do not reach the glycaemic targets even in the centres of excellence. Regular short service messages (SMS) through cell phones could have a positive effect on behaviour and adherence to life style changes and compliance to drugs. It may be practical and feasible to use information technology as an effective and simple tool for motivating patients to adhere to the prescribed treatment regimen.

In diabetic patients, frequent reminders regarding the need for adherence to LSM and drugs by the medical professionals will improve the compliance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In diabetic patients, frequent reminders by the medical professionals on the need for adherence to Life Style Modification (LSM) and drugs will improve the compliance. SMS may be an effective and cheap tool of communication. Improved compliance is likely to result in better glycaemic control.

Out of total number of 200, consecutive randomization of 100 patients each to SMS or usual care arms will be done. Patients in the SMS group will get SMS once in 3 days as a reminder. Patients will be reviewed at 3, 6, 9 and 12 months from the date of randomization

Fasting and 2hr postprandial glucose and HbA1c will be tested during each visit.

At baseline and at the end of the study, lipids, and renal function test will also be done. A validated questionnaire will be used to assess physical activity, diet habits, adherence to drug prescriptions and frequency of monitoring of blood glucose. . Body weight, blood pressure, biochemical variables, scores for diet and physical activity and compliance to drugs, will be compared using students 't' test or chi-square test as relevant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 is experimental with SMS

Arm 1 is experimental with SMS intervention

Group Type EXPERIMENTAL

Pre-coded messages

Intervention Type BEHAVIORAL

Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder

2 is (active comparator) standard care

Arm 2 is the usual care arm (standard care)

Group Type ACTIVE_COMPARATOR

Diabetes Treatment

Intervention Type DRUG

Life style modification and drug therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pre-coded messages

Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder

Intervention Type BEHAVIORAL

Diabetes Treatment

Life style modification and drug therapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, 30-65 yrs of age at the time of entry and have type 2 diabetes for a minimum period of 5 years.
* HbA1C ranging 8.0-10.0%
* Patients either receiving OHA and / or insulin

Exclusion Criteria

* Type 1 diabetes
* Patients with history of blindness, decreased vision
* Serious vascular complications :
* Cancer
Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

INDIA DIABETES RESEARCH FOUNDATION (IDRF) and Dr. A. Ramachandran's Diabetes Hospitals (ARH)

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Samith A Shetty, M.B.B.S, MDRC

Role: PRINCIPAL_INVESTIGATOR

India Diabetes Research Foundation (IDRF) and Dr.A.Ramachandran's Diabetes Hospitals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

India Diabetes Research Foundation and Dr.A.Ramachandran's Diabetes Hospitals

Chennai, Tamil Nadu, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

References

Explore related publications, articles, or registry entries linked to this study.

Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006 Feb;49(2):289-97. doi: 10.1007/s00125-005-0097-z. Epub 2006 Jan 4.

Reference Type BACKGROUND
PMID: 16391903 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SMS001IDRF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Telenhealth and Adherence to Stains
NCT05872919 COMPLETED NA
The Medication Experience Study
NCT01702883 COMPLETED NA
Text Message Study
NCT01789697 TERMINATED NA